… to the clinical development of EGFR-directed drugs will be discussed. These issues may
well apply to many other molecule-targeted strategies in preclinical and clinical development. …

… “off-target” effects, the safety of long-term administration, and the research of new clinical
end points or methodological approaches for the optimal clinical development of these agents. …

… and possible drug combinations. We also review the biomarkers explored in the first clinical
trials, the strategies that have been explored thus far, and the clinical trials that are going to …

… Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to …
biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future …

… clinical trials are the RTK inhibitors and the monoclonal antibodies. The clinical development
of EGFR inhibitors has introduced new challenges to the design of phase I, II, and III trials. …

… have been demonstrated in clinical trials involving subsets of … In this Review, the author
describes the clinical experience with … of the progress of clinical trials involving FGFR-targeted …

… In this review, we summarize the current status of the clinical development of this class of
agents. … concepts that may be useful for the future clinical development of this class of agents. …

… EGFR ligand-toxin and immunotoxin conjugates and antisense oligonucleotides are still
in the early phases of clinical development (phase I/II trials; Table 1). This article will focus on …

… current clinical trials evaluating the efficacy of anti-EGF receptor … of the receptor are also
under study in the clinic. Since … to express high levels of EGF receptors, and production of TGF-α …

… of clinical need. More than two dozen drug candidates have been developed and clinical trials
are … Early clinical trials reveal an acceptable safety profile together with pharmacodynamic …